Literature DB >> 19429866

Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.

Raul Alba1, Angela C Bradshaw, Alan L Parker, David Bhella, Simon N Waddington, Stuart A Nicklin, Nico van Rooijen, Jerome Custers, Jaap Goudsmit, Dan H Barouch, John H McVey, Andrew H Baker.   

Abstract

Recent studies have demonstrated the importance of coagulation factor X (FX) in adenovirus (Ad) serotype 5-mediated liver transduction in vivo. FX binds to the adenovirus hexon hypervariable regions (HVRs). Here, we perform a systematic analysis of FX binding to Ad5 HVRs 5 and 7, identifying domains and amino acids critical for this interaction. We constructed a model of the Ad5-FX interaction using crystallographic and cryo-electron microscopic data to identify contact points. Exchanging Ad5 HVR5 or HVR7 from Ad5 to Ad26 (which does not bind FX) diminished FX binding as analyzed by surface plasmon resonance, gene delivery in vitro, and liver transduction in vivo. Exchanging Ad5-HVR5 for Ad26-HVR5 produced deficient virus maturation. Importantly, defined mutagenesis of just 2 amino acids in Ad5-HVR5 circumvented this and was sufficient to block liver gene transfer. In addition, mutation of 4 amino acids in Ad5-HVR7 or a single mutation at position 451 also blocked FX-mediated effects in vitro and in vivo. We therefore define the regions and amino acids on the Ad5 hexon that bind with high affinity to FX thereby better defining adenovirus infectivity pathways. These vectors may be useful for gene therapy applications where evasion of liver transduction is a prerequisite.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429866      PMCID: PMC2721791          DOI: 10.1182/blood-2009-03-208835

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Methods for reconstructing density maps of "single" particles from cryoelectron micrographs to subnanometer resolution.

Authors:  J F Conway; A C Steven
Journal:  J Struct Biol       Date:  1999-12-01       Impact factor: 2.867

2.  Situs: A package for docking crystal structures into low-resolution maps from electron microscopy.

Authors:  W Wriggers; R A Milligan; J A McCammon
Journal:  J Struct Biol       Date:  1999 Apr-May       Impact factor: 2.867

3.  Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon.

Authors:  J J Rux; R M Burnett
Journal:  Mol Ther       Date:  2000-01       Impact factor: 11.454

4.  Factors influencing retention of adenovirus within tumours following direct intratumoural injection.

Authors:  M Bazan-Peregrino; R C Carlisle; L Purdie; L W Seymour
Journal:  Gene Ther       Date:  2008-02-21       Impact factor: 5.250

5.  Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver.

Authors:  Frédéric Vigant; Delphyne Descamps; Betsy Jullienne; Stéphanie Esselin; Elisabeth Connault; Paule Opolon; Thierry Tordjmann; Emmanuelle Vigne; Michel Perricaudet; Karim Benihoud
Journal:  Mol Ther       Date:  2008-06-17       Impact factor: 11.454

6.  Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity.

Authors:  Dmitry M Shayakhmetov; Anuj Gaggar; Shaoheng Ni; Zong-Yi Li; André Lieber
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes.

Authors:  Doryen Bubeck; David J Filman; Naiqian Cheng; Alasdair C Steven; James M Hogle; David M Belnap
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  Efficient infection of tumor endothelial cells by a capsid-modified adenovirus.

Authors:  K Shinozaki; E Suominen; F Carrick; B Sauter; V-M Kähäri; A Lieber; S L C Woo; M Savontaus
Journal:  Gene Ther       Date:  2006-01       Impact factor: 5.250

9.  Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5.

Authors:  Simon N Waddington; Alan L Parker; Menzo Havenga; Stuart A Nicklin; Suzanne M K Buckley; John H McVey; Andrew H Baker
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

10.  Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.

Authors:  Robert C Carlisle; Ying Di; Anna M Cerny; Andreas F-P Sonnen; Robert B Sim; Nicola K Green; Vladimir Subr; Karel Ulbrich; Robert J C Gilbert; Kerry D Fisher; Robert W Finberg; Leonard W Seymour
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

View more
  96 in total

1.  Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.

Authors:  Raul Alba; Angela C Bradshaw; Lynda Coughlan; Laura Denby; Robert A McDonald; Simon N Waddington; Suzanne M K Buckley; Jenny A Greig; Alan L Parker; Ashley M Miller; Hongjie Wang; Andre Lieber; Nico van Rooijen; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

2.  Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Authors:  Di Yu; Chuan Jin; Justyna Leja; Nadim Majdalani; Berith Nilsson; Fredrik Eriksson; Magnus Essand
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  Construction of metabolically biotinylated adenovirus with deleted fiber knob as targeting vector.

Authors:  Yanzheng Liu; Philippe Valadon; Jan E Schnitzer
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

4.  Targeting adenoviruses with factor x-single-chain antibody fusion proteins.

Authors:  Christopher Y Chen; Shannon M May; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

5.  Real-time recording of circadian liver gene expression in freely moving mice reveals the phase-setting behavior of hepatocyte clocks.

Authors:  Camille Saini; André Liani; Thomas Curie; Pascal Gos; Florian Kreppel; Yann Emmenegger; Luigi Bonacina; Jean-Pierre Wolf; Yves-Alain Poget; Paul Franken; Ueli Schibler
Journal:  Genes Dev       Date:  2013-07-01       Impact factor: 11.361

6.  FX and host defense evasion tactics by adenovirus.

Authors:  Andrew H Baker; Stuart A Nicklin; Dmitry M Shayakhmetov
Journal:  Mol Ther       Date:  2013-06       Impact factor: 11.454

Review 7.  Current issues and future directions of oncolytic adenoviruses.

Authors:  Masato Yamamoto; David T Curiel
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

8.  Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.

Authors:  Sergey A Kaliberov; Lyudmila N Kaliberova; Zhi Hong Lu; Meredith A Preuss; Justin A Barnes; Cecil R Stockard; William E Grizzle; Jeffrey M Arbeit; David T Curiel
Journal:  Virology       Date:  2013-10-15       Impact factor: 3.616

9.  Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo.

Authors:  Anne K Zaiss; Erin M Foley; Roger Lawrence; Lina S Schneider; Hamidreza Hoveida; Patrick Secrest; Arthur B Catapang; Yu Yamaguchi; Ramon Alemany; Dmitry M Shayakhmetov; Jeffrey D Esko; Harvey R Herschman
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

10.  Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.

Authors:  Zhili Xu; Qi Qiu; Jie Tian; Jeffrey S Smith; Gina M Conenello; Takashi Morita; Andrew P Byrnes
Journal:  Nat Med       Date:  2013-03-24       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.